Advertisement

Targeted Oncology

, Volume 14, Issue 1, pp 107–113 | Cite as

Cabozantinib: A Review in Advanced Hepatocellular Carcinoma

  • Emma D. DeeksEmail author
Adis Drug Evaluation

Abstract

Cabozantinib is an inhibitor of multiple receptor tyrosine kinases (RTKs) with roles in cancer pathogenesis. This review focuses on data relevant to the use of cabozantinib tablets (Cabometyx®) in the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with the multi-RTK inhibitor sorafenib, an indication for which cabozantinib tablets are approved in the EU and USA. Approval of cabozantinib in this setting was based largely on the findings of CELESTIAL, a phase 3 trial in adults with advanced HCC who had previously received sorafenib, had progressive disease after at least one systemic therapy and had received up to two systemic treatments for their advanced disease. Compared with placebo in this study, cabozantinib prolonged both overall survival and progression-free survival, with these findings largely unaffected by patient/disease characteristics. The tolerability profile of cabozantinib in CELESTIAL was acceptable and consistent with that of other multi-RTK inhibitors, with adverse events that were manageable with dose modification and supportive care. Thus, cabozantinib is a welcome additional treatment option for use in adults with HCC previously treated with sorafenib.

Notes

Acknowledgements

During the peer review process, the marketing authorization holders of cabozantinib (Exelixis and Ipsen) were also offered the opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefGoogle Scholar
  2. 2.
    Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.CrossRefGoogle Scholar
  3. 3.
    Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv238–55.CrossRefGoogle Scholar
  4. 4.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines)—hepatobiliary cancers [version 3.2018]. 2018. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf Accessed 1 Feb 2019.
  5. 5.
    Desai JR, Ochoa S, Prins PA, et al. Systemic therapy for advanced hepatocellular carcinoma: an update. J Gastrointest Oncol. 2017;8(2):243–55.CrossRefGoogle Scholar
  6. 6.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.CrossRefGoogle Scholar
  7. 7.
    Raoul JL, Kudo M, Finn RS, et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma: sorafenib and beyond. Cancer Treat Rev. 2018;68:16–24.CrossRefGoogle Scholar
  8. 8.
    Exelixis Inc. Cabometyx® (cabozantinib) tablets for oral use: US prescribing information. 2019. https://cabometyx.com/resources. Accessed 15 Jan 2019.
  9. 9.
    Ipsen Pharma. Cabometyx film-coated tablets: EU summary of product characteristics. 2019. https://www.ema.europa.eu. Accessed 4 Feb 2019.
  10. 10.
    Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–308.CrossRefGoogle Scholar
  11. 11.
    Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 2014;20(11):2959–70.CrossRefGoogle Scholar
  12. 12.
    Nguyen L, Benrimoh N, Xie Y, et al. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults. Anticancer Drugs. 2016;27(7):669–78.CrossRefGoogle Scholar
  13. 13.
    Nguyen L, Holland J, Mamelok R, et al. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol. 2015;55(11):1293–302.CrossRefGoogle Scholar
  14. 14.
    Nguyen L, Holland J, Ramies DA, et al. Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib. J Clin Pharmacol. 2016;56(9):1130–40.CrossRefGoogle Scholar
  15. 15.
    Nguyen L, Holland J, Miles D, et al. Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015;55(9):1012–23.CrossRefGoogle Scholar
  16. 16.
    Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63.CrossRefGoogle Scholar
  17. 17.
    Schoffski P, Gordon M, Smith DC, et al. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer. 2017;86:296–304.CrossRefGoogle Scholar
  18. 18.
    Kelley RK, Verslype C, Cohn AL, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017;28(3):528–34.CrossRefGoogle Scholar
  19. 19.
    Merle P, Rimassa L, Ryoo B, et al. Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC) [abstract no. O-011]. Ann Oncol. 2018;29(Suppl 5).Google Scholar
  20. 20.
    Meyer T, Baron A, Gordan J, et al. Outcomes in patients (pts) with hepatitis B virus (HBV) in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). [abstract no. 0-012]. In: International Liver Cancer Association Annual Meeting. 2018.Google Scholar
  21. 21.
    Blanc JF, Meyer T, Cheng AL, et al. Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) [abstract no. 703P plus poster]. Ann Oncol. 2018;29(Suppl 8).Google Scholar
  22. 22.
    Rimassa L, Cicin I, Blanc JF, et al. Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) [abstract no. 4090]. J Clin Oncol. 2018;36(Suppl).Google Scholar
  23. 23.
    Kelley R, El-Khoueiry A, Meyer T, et al. Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC). [abstract no. 702P plus poster]. Ann Oncol. 2018;29(Suppl 8).Google Scholar
  24. 24.
    Yau T, Cheng AL, Meyer T, et al. Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) [abstract no. 704P plus poster]. Ann Oncol. 2018;29(Suppl 8).Google Scholar
  25. 25.
    Kelley RK, Ryoo BY, Merle P, et al. Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). [abstract no. 4088]. J Clin Oncol. 2018;36(Suppl).Google Scholar
  26. 26.
    Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35(21):2687–97.CrossRefGoogle Scholar
  27. 27.
    Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70(24):10090–100.CrossRefGoogle Scholar
  28. 28.
    Kudo M. Cabozantinib as a second-line agent in advanced hepatocellular carcinoma. Liver Cancer. 2018;7(2):123–33.CrossRefGoogle Scholar
  29. 29.
    Ueki T, Fujimoto J, Suzuki T, et al. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology. 1997;25(3):619–23.CrossRefGoogle Scholar
  30. 30.
    Liu J, Wang K, Yan Z, et al. Axl expression stratifies patients with poor prognosis after hepatectomy for hepatocellular carcinoma. PLoS ONE. 2016;11(5):e0154767.CrossRefGoogle Scholar
  31. 31.
    Bakouny Z, Assi T, El Rassy E, et al. Second-line treatments of advanced hepatocellular carcinoma: systematic review and network meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2018.  https://doi.org/10.1097/mcg.0000000000001160.Google Scholar
  32. 32.
    Roskell N, Gregory J, Wisniewski T, et al. Indirect treatment comparisons of nivolumab versus regorafenib, cabozantinib and best supportive care after treatment with sorafenib for hepatocellular carcinoma [poster no. PCN17]. In: ISPOR Europe conference. 2018.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations